Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Chase Knickerbocker
C-H
Chase Knickerbocker
Wall Street Analyst
★★☆☆☆
#1914
on 13Foresight · ranked by our own returns
52%
Success Rate
+42.4%
Average Return
23 of 44 calls profitable · +27.7% vs benchmark
📈 Across the calls we could measure, roughly 52% of Chase Knickerbocker's ratings turned a profit when each position was held for 2 year — averaging +42.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

289 Buy 11 Hold 0 Sell
Chase's Stock Coverage 43 ratings · 2026-06-19
Company Date Position Consensus Price Target 2-Yr Return
ACOG
Alpha Cognition Inc
Jun 17, 2026 BUY Strong Buy
+117.1% avg upside
3 analysts
·
DMAC
Diamedica Therapeutics
Jun 17, 2026 BUY Strong Buy
+153.7% avg upside
12 analysts
·
MDXG
MiMedx Group
Jun 17, 2026 BUY Strong Buy
+185.0% avg upside
17 analysts
·
XERS
Xeris Pharmaceuticals
Jun 11, 2026 BUY Strong Buy
+33.7% avg upside
10 analysts
-0.4%
CVRX
CVRx
Jun 09, 2026 BUY Strong Buy
+136.7% avg upside
9 analysts
·
HROW
Harrow Health
Jun 08, 2026 BUY Strong Buy
+25.5% avg upside
12 analysts
+26.7%
INDV
Indivior
Jun 04, 2026 BUY Strong Buy
+2.1% avg upside
9 analysts
+1.3%
CELC
Celcuity
Jun 03, 2026 BUY Strong Buy
+40.6% avg upside
16 analysts
$171.00
94.84% Upside
-1.0%
BVS
Bioventus
May 22, 2026 BUY Strong Buy
+41.2% avg upside
8 analysts
-7.0%
ETON
Eton Pharmaceuticals
May 20, 2026 BUY Strong Buy
-21.5% avg upside
8 analysts
-4.9%
XTNT
Xtant Medical Holdings
May 13, 2026 BUY Strong Buy
+1451.0% avg upside
9 analysts
-4.2%
IRWD
Ironwood Pharma
May 13, 2026 BUY Hold
+235.8% avg upside
23 analysts
-4.3%
PYPD
PolyPid
May 11, 2026 BUY Strong Buy
+251.6% avg upside
7 analysts
+8.8%
NRXS
NeurAxis, Inc.
May 11, 2026 BUY Strong Buy
+8.0% avg upside
3 analysts
-17.8%
KRMD
REPRO-MED Systems
May 05, 2026 BUY Strong Buy
+64.8% avg upside
9 analysts
+1.5%
PHAT
Phathom Pharmaceuticals
Apr 28, 2026 BUY Strong Buy
+163.5% avg upside
14 analysts
-4.0%
BFLY
Butterfly Network
Apr 28, 2026 BUY Strong Buy
-37.6% avg upside
7 analysts
+9.5%
GRCE
Grace Therapeutics
Apr 24, 2026 BUY Strong Buy
+153.0% avg upside
9 analysts
$4.00
67.97% Upside
+1.3%
DCTH
Delcath Systems
Apr 22, 2026 BUY Strong Buy
+90.3% avg upside
11 analysts
+6.6%
FENC
Fennec Pharmaceuticals
Apr 22, 2026 BUY Strong Buy
+78.1% avg upside
9 analysts
+34.4%
MDWD
Mediwound
Apr 06, 2026 BUY Strong Buy
+51.9% avg upside
13 analysts
-13.8%
MYO
Myomo
Mar 10, 2026 BUY Strong Buy
+464.7% avg upside
9 analysts
$1.10
13.98% Downside
+28.9%
BLBD
Blue Bird
Nov 20, 2025 BUY Strong Buy
-16.5% avg upside
11 analysts
+44.5%
SMTC
Semtech
Nov 19, 2025 BUY Strong Buy
-9.0% avg upside
24 analysts
+145.4%
MXL
Maxlinear
Oct 20, 2025 BUY Buy
-35.8% avg upside
16 analysts
+441.6%
OKLO
Oklo Inc
Oct 17, 2025 HOLD Strong Buy
+59.4% avg upside
24 analysts
-62.8%
LGND
Ligand Pharma
Oct 09, 2025 BUY Strong Buy
-20.8% avg upside
15 analysts
+44.3%
INOD
Innodata
Oct 08, 2025 BUY Strong Buy
+28.5% avg upside
8 analysts
+12.7%
KORU
Direxion MSCI Daily South Korea Bull 3X Shares
Aug 07, 2025 BUY Strong Buy
1 analyst
+997.9%
CDLX
Cardlytics
Jul 23, 2025 HOLD Hold
+349.7% avg upside
16 analysts
-82.7%
AEHR
Aehr Test Systems
Jul 22, 2025 BUY Strong Buy
-46.2% avg upside
4 analysts
+477.1%
NEXN
Nexxen International
Jul 14, 2025 BUY Strong Buy
+32.5% avg upside
16 analysts
-13.4%
TRLV
Trulieve Cannabis
Feb 26, 2025 BUY Strong Buy
+123.5% avg upside
15 analysts
$11.50
13.89% Upside
·
RMNI
Rimini Street
Feb 05, 2025 BUY Strong Buy
+50.3% avg upside
9 analysts
+38.9%
OMCL
Omnicell
Aug 28, 2024 BUY Strong Buy
+36.0% avg upside
12 analysts
-4.6%
ALKT
Alkami Technology
Aug 01, 2024 BUY Strong Buy
+81.4% avg upside
15 analysts
$38.00
158.84% Upside
-53.1%
SPIR
Spire Global
Jul 18, 2024 BUY Strong Buy
-18.4% avg upside
12 analysts
+37.8%
OABI
OmniAb
Mar 21, 2024 BUY Strong Buy
+249.1% avg upside
10 analysts
$10.00
327.37% Upside
-66.0%
CSBR
Champions Oncology
Oct 16, 2023 BUY Strong Buy
+34.6% avg upside
6 analysts
+4.0%
ISPC
iSpecimen
Sep 13, 2023 BUY Strong Buy
+64.1% avg upside
3 analysts
-85.2%
FSLY
Fastly
Aug 18, 2023 BUY Buy
+79.5% avg upside
25 analysts
-63.3%
INFU
InfuSystem Holdings
May 04, 2023 BUY Strong Buy
+62.1% avg upside
7 analysts
-42.8%
ZG
Zillow Group Class A
May 03, 2023 BUY Buy
+95.2% avg upside
45 analysts
$58.00
78.56% Upside
+63.1%
🔒 38 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Chase Knickerbocker — Frequently Asked Questions
How accurate are Chase Knickerbocker's stock ratings?
Based on the calls 13Foresight could measure, about 45% of Chase's ratings were profitable over a one-year hold, with an average return of +39.5% per rating, or +29.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Chase ranked on 13Foresight?
Chase Knickerbocker is currently ranked #1914 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Chase cover?
Chase most recently has ratings on ACOG, DMAC, MDXG, XERS, CVRX, HROW, INDV, CELC, BVS, ETON, XTNT, IRWD and 31 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.